Comparing Immunotherapy and Chemotherapy for Esophageal Cancer
Author Information
Author(s): Zhang Jiao, Zhao Peixi, Xu Rui, Han Le, Chen Wenjuan, Zhang Yili
Primary Institution: Shaanxi Province Tumor Hospital of Xi’an Jiaotong University
Hypothesis
What is the efficacy and safety of different immune checkpoint inhibitors combined with chemotherapy for locally advanced esophageal cancer?
Conclusion
Neoadjuvant immunotherapy combined with chemotherapy shows high efficacy and tolerable safety profiles for treating locally advanced esophageal cancer.
Supporting Evidence
- Neoadjuvant immunochemotherapeutic strategies showed significant advantages over traditional therapy.
- Camrelizumab plus chemotherapy had the highest rates of pathological complete response.
- Pembrolizumab plus chemotherapy achieved the best outcomes in terms of objective response rate.
Takeaway
This study found that using immunotherapy with chemotherapy can help treat esophageal cancer better than just chemotherapy alone.
Methodology
A systematic review and network meta-analysis of 14 studies evaluating various immunotherapy and chemotherapy combinations.
Potential Biases
Some studies had high risk of bias due to inadequate blinding.
Limitations
The study is limited by the lack of direct comparisons between several ICIs and the majority of studies being from China, which may affect generalizability.
Participant Demographics
The included studies predominantly involved male patients with a median age exceeding 60 years.
Statistical Information
P-Value
0.03
Confidence Interval
95% CI, 52.9%-66.1%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website